Intensive topical therapy with dexamethasone .5 mg/5 mL solution is effective for managing patients with new-onset symptomatic oral chronic graft-versus-host disease

The dexamethasone solution results support the most recent National Institutes of Health consensus ancillary care guidelines for management of oral chronic graft-versus-host disease

Topical tacrolimus .5 mg/5 mL solution is less effective than dexamethasone solution for managing patients with new-onset symptomatic oral chronic graft-versus-host disease; however, its relative efficacy and safety at higher concentrations are unknown